Symbicort® COPD (budesonide/formoterol)
Symbicort® Turbohaler® and Symbicort® pMDI are combinations of an inhaled corticosteroid and a long-acting β2-agonist
In England and Wales, the number of emergency hospital admissions for COPD exacerbations has risen by 13% between 2008 and 2014*.10
Extrapolated survival from time of first ever hospitalisation for a COPD exacerbation in Quebec, Canada.11
Adapted from Suissa et al. 201211
A retrospective analysis of 73,106 COPD patients prescribed at least one respiratory medicine and first admitted to hospital for COPD exacerbation, between 1990 and 2005 in Quebec, Canada. The Régie de l’assurance maladie du Québec, health insurance databases formed the database. Subjects were aged over 55 years and those with prior asthma hospitalisation were excluded. Subjects were followed from first hospitalisation for COPD until death or 31 March 2007. The hazard functions of successive hospitalised COPD exacerbations and all-cause mortality over time were estimated. Severe exacerbations were defined as subsequent hospitalisations with a primary discharge diagnosis of COPD, occurring during follow-up.11
Please note that Symbicort® is not currently licensed to treat exacerbations.
*Clinical audit of COPD exacerbations admitted to acute units in England and Wales.10